Capricor Therapeutics, Inc. (CAPR) is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and large molecule products for the treatment of diseases.  As a developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U.S. healthcare industry – heart disease. Capricor Therapeutics’ lead product candidates will target the prevention and treatment of heart failure and heart attacks.  Capricor’s allogeneic cardiosphere-derived cell (CDC) product, CAP-1002, aims to attenuate and potentially improve damage to the heart caused by a heart attack.

Capricor’s translational approach to product development is based on the comprehensive research foundation provided through our academic partnerships with leading scientists at top-tier research institutions.

Capricor and Nile Therapeutics completed a merger in 2013 to form Capricor Therapeutics, Inc. (NASDAQ: CAPR).

http://capricor.com/